Researchers have cautioned that social media platforms are contributing to inappropriate use of blood-based biomarker tests for Alzheimer’s disease among asymptomatic populations. The tests, which detect proteins associated with Alzheimer’s-related brain changes such as p-tau217 and p-tau181, have generated significant interest due to their accessibility compared to alternatives like brain imaging or lumbar punctures. However, major neurological organizations, including the Alzheimer’s Association, have established consensus that these tests should only be used in specific clinical circumstances and never for screening healthy individuals.
Researchers from the University of Sydney analyzed 188 social media posts about Alzheimer’s and blood tests from accounts collectively reaching more than 114 million followers across Facebook, Instagram and TikTok. The analysis found that approximately 10% of posts were from doctors claiming the tests could be useful for asymptomatic screening, with most of these posts originating from the United States. Additionally, more than one-third of all posts promoted the tests for people without symptoms, and accounts with stated financial interests were more than three times as likely to promote testing in asymptomatic populations. The findings were published in the Journal of the American Geriatrics Society.
Clinical experts emphasize that these tests can produce positive results in individuals who may never develop dementia symptoms and should only be ordered by physicians when there is strong clinical indication of early Alzheimer’s disease. A key concern is that healthy people testing positive face uncertainty about treatment options, as existing research on available therapies has focused on individuals with mild cognitive impairment or dementia rather than asymptomatic carriers of biomarkers. Additional risks include psychological impacts of diagnosis, potential side effects from treatments, and insurance implications.
Cost considerations also factor into the concern. When ordered through physicians in Australia, tests range up to $400 and are not covered by Medicare. Direct-to-consumer providers charge between $365 and $600, with some offering minimal pre-test screening. Health authorities note that both false positive and false negative results carry risks, as positive results may create unfounded fears of inevitable dementia while negative results might discourage individuals from addressing modifiable risk factors such as exercise levels, cholesterol management, and hearing or vision health.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI